Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897343 | 0.86 | LPAR1 (0.46) | LPAR1KMT2A | |
| SCHEMBL6890154 | 0.86 | LPAR1 (0.53) | LPAR1KMT2ASMN1; SMN2 | |
| SCHEMBL6896205 | 0.86 | LPAR1 (0.53) | LPAR1KMT2ASMN1; SMN2 | |
| SCHEMBL27538306 | 0.85 | LPAR1 (0.45) | LPAR1ALDH1A1LPAR5KMT2AALOX5 | |
| SCHEMBL6895919 | 0.85 | LPAR1 (0.45) | LPAR1ALDH1A1LPAR5KMT2AALOX5 | |
| SCHEMBL6890174 | 0.85 | HSD17B10 (0.44) | LPAR1ALDH1A1KMT2AAOC3PTGES | |
| SCHEMBL6898167 | 0.85 | LPAR1 (0.43) | LPAR1KMT2AAOC3 | |
| SCHEMBL6891314 | 0.84 | LPAR1 (0.47) | LPAR1KMT2APTGES | |
| SCHEMBL6897944 | 0.83 | KMT2A (0.61) | LPAR1ALDH1A1LPAR5KMT2AALOX5 | |
| SCHEMBL6896834 | 0.82 | LPAR1 (0.43) | LPAR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | LPAR1 4229/4885ALDH1A1 1309/4885LPAR5 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.